Properties |
Information |
PhytoCAT-ID |
PhytoCAT-32 |
Phytochemical name or plant extracts |
Magnoflorine |
PMID |
32325867 |
Literature evidence |
Magnoflorine in combination with cisplatin at a fixed ratio of 1:1 augmented their anticancer action and yielded synergistic or additive pharmacological interactions by means of isobolographic method, therefore combined therapy using these two active agents can be a promising chemotherapy regimen in the treatment of some types of breast, lung, rhabdomyosarcoma, and glioblastoma cancers. |
IUPAC name |
(6aS)-2,10-dimethoxy-6,6-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-6-ium-1,11-diol |
Phytochemicals’ class or type of plant extracts |
Aporphine alkaloid |
Source of phytochemicals or plant Extracts |
Berberidaceae, Magnoliaceae, Menispermaceae, or Papaveraceae botanical families
Berberis cretica |
|
Geographical availability |
Berberis cretica - Cyprus, East Aegean Is., Greece, Kriti, Turkey |
Plant parts |
Root |
Other cancers |
Breast cancer, Glioma, Lung cancer, Myosarcoma |
Target gene or protein |
NA |
Gene or Protein evidence |
NA |
Target pathways |
AKT/mTOR and p38 signaling pathways |
IC50 |
187.32 µg/mL against MDA-MB-468 |
Potency |
MGN in high doses inhibits proliferation, induces apoptosis, and inhibits cell cycle in S/G2 phases in a dose-dependent manner. |
Cell line/ mice model |
NCI-H1299, MDA-MB-468, T98G , TE671 |
Additional information |
MGN seems to be a promising anti-cancer compound in therapy of some types of lung, breast, glioma, and rhabdomyosarcoma cancers, for which current standard therapies are limited or have severe strong side effects.
Magnoflorine improves sensitivity to doxorubicin (DOX) of breast cancer cells via inducing apoptosis and autophagy through AKT/mTOR and p38 signaling pathways. |
PubChem ID |
73337 |
Additional PMIDs |
31707337 33182753 |
Additional sources of information |
https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:106572-1 |
Safety |
NA |